Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2017-10-04 Capital/Financing Update
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about an underwriting agreement for a public offering of common stock and preferred stock, amendments to articles of incorporation (Certificate of Designation), and press releases related to the offering. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The primary focus is on financing activities and capital raising. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (6846 characters) supports it being a full report rather than a brief announcement or certification. Hence, the classification is CAP with high confidence.
2017-10-04 English
SC 13G Filing
Major Shareholding Notification
2017-10-03 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to an offering of Class A and Class B Units consisting of common stock, warrants, and convertible preferred stock. It includes extensive information about the offering terms, underwriting, risk factors, business overview, market opportunity, clinical trial results, and management discussion. The presence of a prospectus, registration number, offering details, and underwriting information clearly identifies this as a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report. It is a primary offering document for securities issuance.
2017-10-02 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for Ritter Pharmaceuticals, Inc. The document includes details about the securities being registered, signatures of company officers, and exhibits such as legal opinions and consents. This type of filing is related to the company's capital raising activities through public offering of securities. It is not an annual report, earnings release, or any other financial report but a capital/financing update related to registration of securities for sale to the public. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a certification, so it is not RPA or RNS.
2017-09-29 English
Regulatory Filings 2017
Regulatory Filings
2017-09-29 English
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 6 to a Form S-1 Registration Statement filed with the SEC by Ritter Pharmaceuticals, Inc. It includes detailed information about the registration of securities under the Securities Act of 1933, including indemnification of directors and officers, recent sales of unregistered securities, and other related disclosures. The Form S-1 is a registration statement used for initial public offerings or other securities offerings, and amendments to it update or add information. This document is not an annual report, earnings release, or other financial report but a regulatory filing related to securities registration and offering. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial and contains detailed legal and financial disclosures typical of an S-1 amendment filing, confirming the classification.
2017-09-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.